HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Court’s Rejection Of Evidence Countering ‘Willful’ Deception On Talc Ends J&J’s Appeal Streak

Executive Summary

Johnson & Johnson failed to convince a Missouri appeals court to overturn a lower court finding that plaintiffs presented clear and convincing evidence the talc in its Johnson’s Baby Powder causes ovarian cancer and that the firm knew and improperly influenced regulators to allow use of the ingredient.

You may also be interested in...

J&J’s Discontinuation Of Johnson’s Baby Powder Linked To April Federal Court Ruling

Legal experts note that J&J’s decision to end Johnson’s Baby Powder sales in the US and Canada closely followed a New Jersey federal court decision that largely denied the firm’s motions to bar testimony from plaintiff experts in multi-district talc litigation comprising around 16,000 cases.

J&J Talc Suit Dismissals: Plaintiffs Lack Causation Thread For Proof Quilt

Following two plaintiff victories and hefty damages awards in a Missouri circuit court earlier this year, J&J succeeded last week in having a pair of talc cancer cases dismissed in New Jersey due to plaintiffs’ lack of compelling causation evidence. With more than 1,000 talc suits against J&J still pending, the relative weight of expert testimonies – and venue – likely will continue to be significant factors in how they play out.

US Meeting Set For CBDs’ Impact On Pregnancies, Gender-Specific Biological, Psychosocial Effects

FDA schedules public meeting for 19 November to discuss sex and gender differences in the use and response to cannabidiols. The meeting will address the issue of CBD use in pregnancy, for which no human data currently is available.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts